Market Overview

FLX Bio to Present at the 2018 Wedbush PacGrow Healthcare Conference


FLX Bio, Inc., a clinical-stage biopharmaceutical company focused on the
discovery and development of oral small-molecule drugs to activate the
immune system, today announced that Brian Wong, M.D., Ph.D., CEO will
present at the 2018 Wedbush PacGrow Healthcare Conference on August 15,
2018 at 12:45 p.m. ET in New York.

A live webcast and audio archive of the presentation may be accessed
here or on the FLX Bio website at
Please connect to the website 10 minutes prior to the presentation to
ensure adequate time for any software downloads that may be necessary to
listen to the webcast.

About FLX Bio

FLX Bio, Inc. is an immuno-oncology company focused on the discovery and
development of orally-available, small molecule drugs targeting key
driver pathways of the tumor microenvironment. Using its integrated
immuno-oncology drug discovery platform, FLX Bio's small molecule
compounds specifically target proteins and pathways important for
regulatory T cells or myeloid cells within the tumor microenvironment.
Its lead candidate FLX475, a best-in-class CCR4 inhibitor, entered Phase
1 studies in December 2017 and has the potential to be used alone or in
combination with checkpoint inhibitors to treat a variety of cancers.
The company employs a precision medicine strategy for prospective
patient selection in clinical studies, applying its robust computational
and translational biology capabilities to identify key biomarkers that
should maximize clinical response and increase the probability of
clinical success. In addition, FLX is developing small molecule
inhibitors of GCN2, a stress response kinase that detects amino acid
starvation in the tumor microenvironment.

Located in South San Francisco, Calif., and funded by leading investors,
including The Column Group (TCG), Kleiner Perkins (KP), Topspin
Partners, GV (formerly Google Ventures) and Celgene Corporation, FLX Bio
has assembled a leadership team and advisory group with a proven track
record of success and team of scientists with substantial knowledge and
expertise in drug discovery and translational areas essential to execute
on this approach. For more information, please visit

View Comments and Join the Discussion!